Pentraxin-3 (PTX-3) is derived from the secretion of macrophages, neutrophils, endothelial cells, epithelial cells, and vascular smooth muscle cells, which can regulate the immune activity of macrophages. The objectives of our study were to investigate the serum PTX-3 levels and analyze this correlation with vasculitis (Vas), with hypertension. A total of 155 cases consisting 51 patients with Vas [including 7 cases of takayasu arteritis (TA), 24 cases of polyarteritis nodosa (PAN), and 20 cases of antineutrophil cytoplasmic antibody-associated Vas (AAV)] were screened by angiography and/or biopsy; 46 patients with essential hypertensions (PH) and 58 healthy controls (HC) were enrolled in this study from January 2013 to December 2016. Serum PTX-3 levels were determined by enzyme-linked immunosorbent assay. Compared with the HC and PH, the serum PTX-3 levels in systemic Vas were significantly higher (both P < 0.001, 4.42 ± 0.95 vs. 2.67 ± 0.92 and 4.42 ± 0.95 vs. 2.95 ± 0.60), and there was no significant difference between HC and essential hypertension (P = 0.886, 2.67 ± 0.92 vs. 2.95 ± 0.60). There was no significant difference of PTX-3 levels among TA, PAN, and AAV, as well as active and inactive groups, and renal and nonrenal groups even if they had a significant difference from EH and HC, respectively. There was no significant correlation between PTX-3 levels and blood pressure, erythrocyte sedimentation rate, or Birmingham Vasculitis Activity Score. Receiver operating characteristic analysis has shown that the best cutoff point was at 3.618 ng/μL; the sensitivity and specificity were calculated as 84.3% and 93.5% for the diagnosis of Vas from heath control, and the best cutoff point was at 3.425 ng/μL, The sensitivity and specificity were calculated as 88.2% and 82.6% for the diagnosis of Vas from essential hypertension. Serum PTX-3 levels were significantly higher in patients with Vas than essential hypertension or health control, and elevated PTX-3 levels can help identify Vas patients from healthy or essential hypertensive populations.

中文翻译：

---

高血压血管炎患者血清Pentraxin-3水平的研究。

Pentraxin-3（PTX-3）来源于巨噬细胞，嗜中性粒细胞，内皮细胞，上皮细胞和血管平滑肌细胞的分泌，可以调节巨噬细胞的免疫活性。我们研究的目的是调查血清PTX-3水平，并分析与血管炎（Vas）和高血压的相关性。通过血管造影和//筛查了总共155例患者，其中包括51例Vas [包括7例高隆动脉炎（TA），24例多发性多发性动脉炎（PAN）和20例抗中性粒细胞胞浆抗体相关的Vas（AAV）]。或活检；2013年1月至2016年12月，本研究共入选46例原发性高血压（PH）和58例健康对照（HC）患者。通过酶联免疫吸附测定法测定血清PTX-3水平。与HC和PH相比，全身性Vas的血清PTX-3水平显着升高（P <0.001，4.42±0.95 vs. 2.67±0.92和4.42±0.95 vs. 2.95±0.60），HC和原发性高血压之间无显着差异（P = 0.886、2.67±0.92和2.95±0.60）。即使在TA，PAN和AAV以及活动和非活动组以及肾和非肾组中，PTX-3的水平也没有显着差异，即使它们分别与EH和HC有显着差异。PTX-3水平与血压，红细胞沉降率或伯明翰血管炎活性评分之间无显着相关性。接收器工作特性分析表明，最佳截止点为3.618 ng /μL；通过健康控制诊断Vas的敏感性和特异性分别为84.3％和93.5％，最佳临界点为3.425 ng /μL，计算出的诊断原发性高血压患者的敏感性和特异性分别为88.2％和82.6％。Vas患者的血清PTX-3水平明显高于原发性高血压或健康控制，升高的PTX-3水平可帮助从健康或原发性高血压人群中识别Vas患者。